Last updated: February 13, 2026
What is the Product Associated with NDC 64896-0675?
NDC 64896-0675 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody approved by the FDA for treating multiple sclerosis (MS). It is marketed by Genentech/Roche and primarily used for relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
Current Market Landscape
Market Size
The global multiple sclerosis market was valued at approximately $20 billion in 2022. The U.S. accounts for approximately 50% of this market.
Key Competitors
- Ocrevus (ocrelizumab): Market share about 25%.
- Tysabri (natalizumab): 20%.
- Tecfidera (dimethyl fumarate): 15%.
- Mayzent (siponimod): 10%.
- Other therapies (e.g., Aubagio, Gilenya) occupy the remaining 30%.
Market Drivers
- Increasing prevalence of MS, especially in North America and Europe.
- Rising diagnosis rates due to improved diagnostic criteria.
- Growing preference for high-efficacy biologics like Ocrevus.
- Expanded indications, including primary progressive MS.
Market Challenges
- High drug costs affecting access and reimbursement.
- Competition from biosimilars in development.
- Safety concerns, such as infection risk associated with immunosuppressive therapies.
Price Dynamics and Projections
Current Pricing
- List price of Ocrevus in the U.S.: Approximately $65,000 to $70,000 per year for a typical dosing regimen.
- Average wholesale price (AWP) is slightly higher, but net prices vary based on discounts, rebates, and insurance negotiations.
Pricing Trends
- Since FDA approval in 2017, pricing has remained relatively stable, with annual increases of around 2-3%.
- Prices are expected to maintain stability through 2025 due to high brand loyalty and limited biosimilar penetration.
Future Price Projections (2023-2030)
| Year |
Estimated Price Range (per year) |
Assumptions |
| 2023 |
$65,000 - $70,000 |
Current pricing stability anticipated. |
| 2025 |
$67,000 - $72,000 |
Slight inflation, competitive pressures limited. |
| 2030 |
$70,000 - $75,000 |
Price asymptote expected barring biosimilar entry. |
Key factors influencing future prices:
- Launch of biosimilars, potentially as early as 2027 in the U.S., which could exert downward pressure.
- Policy shifts towards value-based pricing and cost containment measures.
- Continued growth of MS prevalence, supporting sustained high prices.
Regulatory and Policy Influences
- The U.S. Inflation Reduction Act (2022) encourages price negotiations on Medicare drugs, possibly influencing branded prices.
- European markets are stricter on drug pricing, often resulting in lower prices relative to the U.S.
Market Penetration Outlook
- Ocrevus is entrenched as a first-line therapy for MS with a high efficacy profile.
- Market share is likely to plateau unless biosimilar or generic options are introduced.
- Growth expected primarily from new indications and expanding geographic access.
Investment and R&D Insights
- Roche is investing in next-generation anti-inflammatory biologics, but Ocrevus remains the flagship for MS.
- Biosimilar development is advancing, with clinical trials in late phases, but patient and physician loyalty could delay market entry [1].
Key Takeaways
- The drug associated with NDC 64896-0675, Ocrevus, has a stable, high price point averaging $65,000-$70,000 annually.
- Market share is approximately 25%, with room for growth driven by rising MS prevalence.
- Price projections estimate stability through 2025, with slight increases up to $75,000 by 2030, barring biosimilar competition.
- Biosimilar entry anticipated post-2026 could influence future pricing and market dynamics.
- Regulatory trends and payer policies will shape long-term pricing and access strategies.
FAQs
1. What factors could cause Ocrevus prices to decline?
Introduction of biosimilars, policy reforms targeting drug prices, and increased negotiations with payers.
2. How does Ocrevus compare in cost to other MS therapies?
Ocrevus is among the most expensive MS treatments, with annual costs around $65,000, higher than oral options like Tecfidera (~$60,000) and lower than some newer biologics.
3. What is the likelihood of biosimilar entrants impacting Ocrevus prices?
Biosimilars are in late-phase development; market entry is feasible by 2026-2027, which could reduce prices by 20-40%.
4. How do international prices for Ocrevus differ from the U.S.?
European and other markets generally see lower prices due to stricter reimbursement controls and negotiation powers of health authorities.
5. What are the main factors driving growth in the MS treatment market?
Increasing diagnosis rates, expanded indications, and the adoption of high-efficacy biologics like Ocrevus.
References
[1] Source: FDA Drug Approvals and Market Reports (2022-2023).
